As July enters its second week, Medtronic plc is facing an onslaught of regulatory issues, including patent lawsuits, antitrust cases and cybersecurity vulnerabilities.
The Cybersecurity and Infrastructure System Agency (CISA) reported a vulnerability in Medtronic’s Paceart Optima System that could allow for “remote code execution or a denial-of-service condition impacting a healthcare delivery organization’s Paceart Optima system,” the agency
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?